2 Breakout Biotech Stocks With CEO Insider Buying

Investing in biotech stocks can be risky, particularly in the clinical stage, since their success often hinges on the results of trial data and regulatory developments. Additionally, it can take years for pre-revenue companies to bring a potential bloc…

Analyst Expectations For Insulet’s Future

Insulet (NASDAQ:PODD) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 da…